FDA March 3, 2021

By: Janet Woodcock, M.D., Acting Commissioner of Food and Drugs, and Amy Abernethy, M.D., Ph.D., Principal Deputy Commissioner & Acting Chief Information Officer

With the near ubiquity of interconnected smartphones and computers in modern life, it can be difficult to remember just how quickly our familiarity with data has evolved. Data, in digital form, seem to be everywhere we look. Yet, we are still at an early stage in our ability to apply data to understand and treat disease and address other public health challenges. At this early stage, even small advances in our ability to gain useful insights from data can represent significant opportunities.

In September 2019, when we announced the U.S. Food and Drug Administration’s Technology Modernization Action...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Big Data, FDA, Govt Agencies, Healthcare System, Public Health / COVID, Technology
Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
FDA approves Akebia anemia pill, two years after rejection
FDA Approves Winrevair, Merck’s Novel Treatment for Pulmonary Arterial Hypertension
FDA approves Merck drug for rare lung disorder
Neuronetics wins FDA clearance for device to treat adolescents with depression

Share This Article